RU99112124A - CONFORMATION-LIMITED Analogs of LG-WG, THEIR APPLICATION AND THE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS - Google Patents
CONFORMATION-LIMITED Analogs of LG-WG, THEIR APPLICATION AND THE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONSInfo
- Publication number
- RU99112124A RU99112124A RU99112124/04A RU99112124A RU99112124A RU 99112124 A RU99112124 A RU 99112124A RU 99112124/04 A RU99112124/04 A RU 99112124/04A RU 99112124 A RU99112124 A RU 99112124A RU 99112124 A RU99112124 A RU 99112124A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- formula
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 17
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 108010016626 Dipeptides Proteins 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- -1 aromatic D-amino acid Chemical class 0.000 claims 4
- 239000003163 gonadal steroid hormone Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 108010091748 peptide A Proteins 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 102000006771 Gonadotropins Human genes 0.000 claims 2
- 108010086677 Gonadotropins Proteins 0.000 claims 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 2
- 102000004317 Lyases Human genes 0.000 claims 2
- 108090000856 Lyases Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002622 gonadotropin Substances 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 125000003941 D-tryptophan group Chemical group [H]C1=C([H])C([H])=C2C(C([C@@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims 1
- 206010054834 Hypergonadism Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000000509 Infertility Diseases 0.000 claims 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 1
- 206010061232 Lymphoproliferative disease Diseases 0.000 claims 1
- 241001102832 Meseres Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001548 androgenic Effects 0.000 claims 1
- 230000001833 anti-estrogenic Effects 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000003054 hormonal Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
Claims (28)
V-W-X-SPL-Y-Pro-Z
в которой V означает пептид A1A2, в котором A1 означает pGlu, AcSar или ароматическую D-аминокислоту и A2 означает прямую связь, His, DPhe, DpFPhe или DpClPhe;
W означает ароматическую L- или D-аминокислоту;
X означает дипептид A3A4, в котором A3 означает Ala, Thr, Ser, Dser, Ser(Obzl) или MeSer и A4 означает Tyr, Phe, cPzACAla, L - или D-PicLys, L - или D-NicLys или L - или D-IprLys;
SPL означает спиролактам формулы
Y означает дипептид A5A6, в котором A5 означает аминокислоту с (C1 - C8) алкильной или (C3 - C6) циклоалкильной боковой цепью и A6 означает L- или D-(Arg, Harg, Lys, HLys, Orn, Cit, Hcit или Aph), где L- или D-(Arg и Harg) могут быть замещены одной или двумя (C1 - C4) алкильными группами, и L- или D-(Lys, Hlys, Orn или Aph) могут быть замещены изопропильной, никотиноильной или пиколиноильной группами; и
Z означает GlyNH2, DAlaNH2, AzaGlyNh2 или -NHR1, где R1 означает (C1 - C4) алкил, необязательно замещенный гидрокси или одним или несколькими атомами фтора; (C3 - C6) циклоалкил или гетероциклический радикал, выбранный из морфолинила, пирролидинила и пиперидила,
и его фармацевтически приемлемые соли.1. The peptide of the formula (SEQ ID 1)
VWX-SPL-Y-Pro-Z
in which V is a peptide A 1 A 2 , in which A 1 means pGlu, AcSar or an aromatic D-amino acid and A 2 means a direct bond, His, DPhe, DpFPhe or DpClPhe;
W is an aromatic L- or D-amino acid;
X means the dipeptide A 3 A 4 , in which A 3 means Ala, Thr, Ser, Dser, Ser (Obzl) or MeSer and A 4 means Tyr, Phe, cPzACAla, L - or D-PicLys, L - or D-NicLys or L - or D-IprLys;
SPL means spirolactam of the formula
Y means the dipeptide A 5 A 6 , in which A 5 means an amino acid with (C 1 - C 8 ) alkyl or (C 3 - C 6 ) cycloalkyl side chain and A 6 means L- or D- (Arg, Harg, Lys, HLys, Orn, Cit, Hcit or Aph), where L- or D- (Arg and Harg) may be substituted with one or two (C 1 -C 4 ) alkyl groups, and L- or D- (Lys, Hlys, Orn or Aph) may be substituted with isopropyl, nicotinoyl or picolinosyl groups; and
Z means GlyNH 2 , DAlaNH 2 , AzaGlyNh 2 or -NHR 1 , where R 1 means (C 1 -C 4 ) alkyl, optionally substituted by hydroxy or one or more fluorine atoms; (C 3 - C 6 ) cycloalkyl or heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl,
and its pharmaceutically acceptable salts.
V-W-X-SPL-Y-Pro-Z ( IIа)
в которой V означает дипептид A1A2, в котором A1 означает pGlu или AcSar; и A2 означает His;
W означает ароматическую аминокислоту L-серии;
X означает дипептид A3A4, в котором A3 определен, как в (I) в п.1 и A4 означает Tyr или Phe;
SPL определен, как в (I) в п.1;
Y означает дипептид A5A6, в котором A5 определен, как в (I) в п.1 и A6 означает Arg, Lys, HArg, HLys, Orn, Cit или Hcit; и
Z означает GlyNH2 AzaGlyNH2 или -NHR1, где R1 определен, как в (I) в п. 1,
и его фармацевтически приемлемые соли.2. The peptide according to claim 1 of the formula (SEQ ID 2)
VWX-SPL-Y-Pro-Z (IIa)
in which V denotes a dipeptide A 1 A 2 , in which A 1 means pGlu or AcSar; and A 2 is His;
W means an aromatic amino acid of the L-series;
X is the dipeptide A 3 A 4 , in which A 3 is defined as in (I) of claim 1 and A 4 is Tyr or Phe;
SPL is defined as in (i) in claim 1;
Y means the dipeptide A 5 A 6 , in which A 5 is defined as in (I) of claim 1 and A 6 means Arg, Lys, HArg, HLys, Orn, Cit or Hcit; and
Z means GlyNH 2 AzaGlyNH 2 or -NHR 1 , where R 1 is defined as in (I) in claim 1,
and its pharmaceutically acceptable salts.
A1-His-W-A3-Tur-SPL-A5-Arg-Pro-GlyNH2 (IIIa)
в которой A1, W, A3 и A5 определены, как в формуле (IIа) в п.2,
и его фармацевтически приемлемые соли.3. The peptide according to claim 2 of the formula (SEQ ID 4)
A 1 -His-WA 3 -Tur-SPL-A 5 -Arg-Pro-GlyNH 2 (IIIa)
in which A 1 , W, A 3 and A 5 are defined as in formula (IIa) in item 2,
and its pharmaceutically acceptable salts.
A1-His-W-Ser-Tyr-SPL-A5-Arg-Pro-NEt (IVa)
в которой A1, W и A5 определены, как в формуле (IIа) в п.2,
и его фармацевтически приемлемые соли.6. The peptide according to claim 2 of the formula (SEQ ID 5)
A 1 -His-W-Ser-Tyr-SPL-A 5 -Arg-Pro-NEt (IVa)
in which A 1 , W and A 5 are defined as in formula (IIa) in item 2,
and its pharmaceutically acceptable salts.
A1-His-W-Ser-Tyr-SPL-A5-Arg-Pro-AzaGlyNH2 (Va)
в которой A1, W и A5 определены, как в формуле (IIа) в п.2,
и его фармацевтически приемлемые соли.7. The peptide according to claim 2 of the formula (SEQ ID 6)
A 1 -His-W-Ser-Tyr-SPL-A 5 -Arg-Pro-AzaGlyNH 2 (Va)
in which A 1 , W and A 5 are defined as in formula (IIa) in item 2,
and its pharmaceutically acceptable salts.
V-W-X-SPL-Y-Pro-Z (IIb)
в которой V означает пептид A1A2, в котором A1 означает pGlu или ароматическую D-аминокислоту; и A2 означает прямую связь, DPhe, DpFPe или DpClPhe;
W означает Trp, DTrp, DPhe, DpClPhe, DNal, Dpal или DBal;
X означает дипептид A3A4, в котором A3 означает Ser и A4 означает Tyr, Phe, cPzACAla, L- или D-PicLys, L- или D-NicLys или L- или D-IprLys;
SPL определен, как в (I) в п.1;
Y означает пептид A5A6, в котором A5 и A6 определены, как в (I) в п.1; и
Z означает GlyNH2 или DAlaNH2,
и его фармацевтически приемлемые соли.8. The peptide according to claim 1 of the formula (SEQ ID 3)
VWX-SPL-Y-Pro-Z (IIb)
in which V means peptide A 1 A 2 , in which A 1 means pGlu or an aromatic D-amino acid; and A 2 is a direct bond, DPhe, DpFPe or DpClPhe;
W is Trp, DTrp, DPhe, DpClPhe, DNal, Dpal or DBal;
X is the dipeptide A 3 A 4 , in which A 3 is Ser and A 4 is Tyr, Phe, cPzACAla, L- or D-PicLys, L- or D-NicLys, or L- or D-IprLys;
SPL is defined as in (i) in claim 1;
Y means peptide A 5 A 6 , in which A 5 and A 6 are defined as in (I) of claim 1; and
Z means GlyNH 2 or DAlaNH 2 ,
and its pharmaceutically acceptable salts.
A1-A2-W-Ser-A4-SPL-A5-A6-Pro-Z (II'b)
в которой A1, A2, W, A4, A5, A6 и Z определены, как в формуле (IIb) в п. 8,
и его фармацевтически приемлемые соли.9. The peptide of claim 8 of the formula (SEQ ID 8)
A 1 -A 2 -W-Ser-A 4 -SPL-A 5 -A 6 -Pro-Z (II'b)
in which A 1 , A 2 , W, A 4 , A 5 , A 6 and Z are defined as in formula (IIb) in section 8,
and its pharmaceutically acceptable salts.
A1-A2-W-Ser-Tyr-SPL-A5-Arg-Pro-Z (IIIb)
в которой A1, A2, A5, W и Z определены, как в формуле (IIb) в п.8,
и его фармацевтически приемлемые соли.10. The peptide of claim 8 of the formula (SEQ ID 7)
A 1 -A 2 -W-Ser-Tyr-SPL-A 5 -Arg-Pro-Z (IIIb)
in which A 1 , A 2 , A 5 , W and Z are defined as in formula (IIb) in claim 8,
and its pharmaceutically acceptable salts.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96402441.8 | 1996-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU99112124A true RU99112124A (en) | 2001-04-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1263500A (en) | Gnrh antagonists ii | |
US7732412B2 (en) | Methods of treatment using novel LHRH antagonists having improved solubility properties | |
KR900007083B1 (en) | Gnrh antagonists | |
KR100582510B1 (en) | LH-RH peptide analogues, their uses and pharmaceutical compositions containing them | |
KR970701730A (en) | GnRH antagonist (GNRH ANTAGONISTS) | |
EP0448687A1 (en) | Therapeutic decapeptides | |
EP0175506A2 (en) | GnRH antagonists | |
HU211603A9 (en) | Nonapeptide bombesin antagonists | |
KR900007864B1 (en) | Gnrh antagonists ix | |
HU186877B (en) | Process for preparing new hormone antagonists releasing luteinizing hormone and acid addition salts thereof | |
EP0162575A2 (en) | GnRH Antagonists VII | |
NZ200125A (en) | Gonadotropin antagonistic peptide derivatives | |
US6153587A (en) | Conformationally constrained LH-RH analogues, their uses and pharmaceutical compositions containing them | |
HU190949B (en) | Process for producing peptides antagonistic with hormones for releasing gonadotropine | |
EP0038135B1 (en) | Lrf antagonists | |
RU99112124A (en) | CONFORMATION-LIMITED Analogs of LG-WG, THEIR APPLICATION AND THE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
IE58287B1 (en) | Spiro-heteroazolones for treatment of diabetes complications | |
HU185308B (en) | Process for preparing peptides influencing gonadotropic hormones | |
US6297354B1 (en) | Pentapeptide LHRH antagonists | |
KR910002702B1 (en) | Method for producing peptide | |
CA1186302A (en) | Lrf antagonists | |
MXPA99004512A (en) | Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them | |
WO2000009545A1 (en) | Pentapeptide lhrh analogs |